MX2014013367A - Composiciones organicas para tratar enfermedades relacionadas con kras. - Google Patents
Composiciones organicas para tratar enfermedades relacionadas con kras.Info
- Publication number
- MX2014013367A MX2014013367A MX2014013367A MX2014013367A MX2014013367A MX 2014013367 A MX2014013367 A MX 2014013367A MX 2014013367 A MX2014013367 A MX 2014013367A MX 2014013367 A MX2014013367 A MX 2014013367A MX 2014013367 A MX2014013367 A MX 2014013367A
- Authority
- MX
- Mexico
- Prior art keywords
- lung
- related diseases
- cancer
- kras
- syndrome
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title 1
- 206010009944 Colon cancer Diseases 0.000 abstract 2
- 108091030071 RNAI Proteins 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000009368 gene silencing by RNA Effects 0.000 abstract 2
- 210000004072 lung Anatomy 0.000 abstract 2
- 201000002927 Cardiofaciocutaneous syndrome Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 abstract 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010029748 Noonan syndrome Diseases 0.000 abstract 1
- 208000024770 Thyroid neoplasm Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 208000009956 adenocarcinoma Diseases 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 230000002357 endometrial effect Effects 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 201000005249 lung adenocarcinoma Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 208000025113 myeloid leukemia Diseases 0.000 abstract 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 1
- 230000002611 ovarian Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 230000002381 testicular Effects 0.000 abstract 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 1
- 210000003932 urinary bladder Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261641588P | 2012-05-02 | 2012-05-02 | |
| PCT/US2013/038847 WO2013166004A2 (en) | 2012-05-02 | 2013-04-30 | Organic compositions to treat kras-related diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014013367A true MX2014013367A (es) | 2014-12-08 |
Family
ID=48366565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014013367A MX2014013367A (es) | 2012-05-02 | 2013-04-30 | Composiciones organicas para tratar enfermedades relacionadas con kras. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20150238515A1 (OSRAM) |
| EP (3) | EP3272868A1 (OSRAM) |
| JP (1) | JP2015517466A (OSRAM) |
| KR (1) | KR20150004414A (OSRAM) |
| CN (2) | CN104583406A (OSRAM) |
| AU (5) | AU2013256471A1 (OSRAM) |
| BR (1) | BR112014027337A2 (OSRAM) |
| CA (2) | CA2872304C (OSRAM) |
| EA (1) | EA201492004A1 (OSRAM) |
| HK (1) | HK1206387A1 (OSRAM) |
| MX (1) | MX2014013367A (OSRAM) |
| WO (1) | WO2013166004A2 (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201620525A (zh) * | 2014-03-14 | 2016-06-16 | 波士頓生醫公司 | 使ｋ－ｒａｓ靜默之非對稱干擾ｒｎａ組成物及其使用方法 |
| MX377654B (es) | 2014-05-14 | 2025-03-11 | Targimmune Tharapeutics Ag | Vectores mejorados de polietilenimina polietilenglicol. |
| US11180759B2 (en) * | 2016-01-19 | 2021-11-23 | The University Of North Carolina At Chapel Hill | Methods and compositions using RNA interference and antisense oligonucleotides for inhibition of KRAS |
| MA45470A (fr) * | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Acides nucléiques kras et leurs utilisations |
| MA45328A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
| KR102543645B1 (ko) * | 2016-07-20 | 2023-06-16 | 주식회사 지씨지놈 | 유전성 발달장애 진단용 조성물 및 이의 용도 |
| JP7506601B2 (ja) | 2017-12-06 | 2024-06-26 | アビディティー バイオサイエンシーズ，インク． | 筋萎縮症と筋緊張性ジストロフィーを処置するための組成物および方法 |
| AU2020287343A1 (en) * | 2019-06-05 | 2021-12-09 | Southern Research Institute | Thiarabine- and thiarabine prodrug-based treatments |
| EP4058152A4 (en) * | 2019-11-14 | 2024-05-08 | The Board of Regents of the University of Oklahoma | PROSTATE CANCER TREATMENTS USING OLIGONUCLEOTIDES INTERFERENCE |
| CA3172111A1 (en) | 2020-03-19 | 2021-09-23 | Barbora MALECOVA | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
| EP4100530A4 (en) * | 2020-04-07 | 2024-05-22 | The University of North Carolina at Chapel Hill | METHODS AND COMPOSITIONS USING RNA INTERFERENCE AND ANTISENSE OLIGONUCLEOTIDES FOR INHIBITION OF KRAS |
| WO2023034537A1 (en) * | 2021-09-02 | 2023-03-09 | Molecular Axiom, Llc | Compositions and methods for modulating kras expression |
| CN118265544A (zh) | 2021-09-16 | 2024-06-28 | 艾维迪提生物科学公司 | 治疗面肩肱型肌营养不良的组合物和方法 |
| WO2024155770A2 (en) * | 2023-01-18 | 2024-07-25 | Molecular Axiom, Llc | Compositions for modulating kras expression and uses thereof |
| EP4669752A1 (en) * | 2023-02-22 | 2025-12-31 | Altamira Therapeutics AG | KRAS COMPOSITIONS AND INHIBITION METHODS FOR THE TREATMENT OF A DISEASE |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5030453A (en) | 1983-03-24 | 1991-07-09 | The Liposome Company, Inc. | Stable plurilamellar vesicles |
| US6977244B2 (en) | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
| US5891467A (en) | 1997-01-31 | 1999-04-06 | Depotech Corporation | Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes |
| EP2314700A1 (en) | 1999-01-28 | 2011-04-27 | Medical College of Georgia Research Institute, Inc | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| CA2403397A1 (en) | 2000-03-16 | 2001-09-20 | Genetica, Inc. | Methods and compositions for rna interference |
| US6680068B2 (en) | 2000-07-06 | 2004-01-20 | The General Hospital Corporation | Drug delivery formulations and targeting |
| US20040234586A1 (en) | 2001-06-11 | 2004-11-25 | Sylvain Meloche | Compositions and methods for enhancing nucleic acid transfer into cells |
| ATE468861T1 (de) | 2001-08-16 | 2010-06-15 | Univ Pennsylvania | Synthese und verwendung von reagenzien für die verbesserte dna-lipofektion und/oder prodrug- und arzneimitteltherapien mit langsamer freisetzung |
| ATE485031T1 (de) | 2002-06-28 | 2010-11-15 | Protiva Biotherapeutics Inc | Verfahren und vorrichtung zur herstellung von liposomen |
| EP1658304A4 (en) | 2002-09-28 | 2009-01-14 | Massachusetts Inst Technology | THERAPY ANTIGRIPPALE |
| EP1560931B1 (en) * | 2002-11-14 | 2011-07-27 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| ES2343318T3 (es) | 2002-11-26 | 2010-07-28 | University Of Massachusetts | Administracion de arnsis. |
| WO2004064731A2 (en) | 2003-01-14 | 2004-08-05 | University Of Washington | Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymlplhoid tissues |
| ES2559828T3 (es) | 2003-07-16 | 2016-02-16 | Protiva Biotherapeutics Inc. | ARN de interferencia encapsulado en lípidos |
| EP2489737A1 (en) | 2003-08-28 | 2012-08-22 | Novartis AG | Interfering RNA duplex having blunt-ends and 3'-modifications |
| EP1682661A2 (en) * | 2003-10-23 | 2006-07-26 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
| EP1714970A1 (en) * | 2005-04-22 | 2006-10-25 | Universität des Saarlandes | Use of inhibitors of RNAse A-family enzymes for stabilizing oligonucleotides having RNA interfering activity |
| CA2628300C (en) | 2005-11-02 | 2018-04-17 | Protiva Biotherapeutics, Inc. | Modified sirna molecules and uses thereof |
| DK2002004T3 (en) | 2006-03-23 | 2015-11-30 | Roche Innovation Ct Copenhagen As | LITTLE INTERNAL SEGMENTED INTERFERENCE RNA |
| GB0608838D0 (en) | 2006-05-04 | 2006-06-14 | Novartis Ag | Organic compounds |
| AU2007299705B2 (en) * | 2006-09-22 | 2012-09-06 | Dharmacon, Inc. | Duplex oligonucleotide complexes and methods for gene silencing by RNA interference |
| EP2121925A2 (en) * | 2007-03-02 | 2009-11-25 | MDRNA, Inc. | Nucleic acid compounds for inhibiting ras gene expression and uses thereof |
| MX2009012568A (es) | 2007-05-22 | 2009-12-08 | Mdrna Inc | Oligonucleotidos de acido ribonucleico sustituidos con hidroximetilo y complejos de acido ribonucleico. |
| CA2704737A1 (en) * | 2007-09-18 | 2009-09-03 | Intradigm Corporation | Compositions comprising k-ras sirna and methods of use |
| WO2009062199A1 (en) * | 2007-11-09 | 2009-05-14 | Fox Chase Cancer Center | EGFR/NEDD9/TGF-β LNTERACTOME AND METHODS OF USE THEREOF FOR THE IDENTIFICATION OF AGENTS HAVING EFFICACY IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS |
| ES2535419T3 (es) | 2007-12-27 | 2015-05-11 | Protiva Biotherapeutics Inc. | Silenciamiento de expresión de quinasa tipo polo usando ARN interferente |
| US8188060B2 (en) | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
| US20110218334A1 (en) * | 2008-07-11 | 2011-09-08 | Alnylam Pharmaceuticals, Inc. | PHOSPHOROTHIOATE OLIGONUCLEOTIDES AND NON-NUCLEOSIDIC PHOSPHOROTHIOATES AS DELIVERY AGENTS FOR iRNA AGENTS |
| ES2921573T3 (es) * | 2009-04-03 | 2022-08-29 | Dicerna Pharmaceuticals Inc | Métodos y composiciones para la inhibición específica de KRAS por RNA bicatenario asimétrico |
| WO2010115202A2 (en) * | 2009-04-03 | 2010-10-07 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of kras by blunt ended double-stranded rna |
| SG181904A1 (en) | 2009-12-23 | 2012-07-30 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| EP2544671A2 (en) * | 2010-03-12 | 2013-01-16 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Pharmaceutical composition for the treatment of chlamydial infection |
-
2013
- 2013-04-30 MX MX2014013367A patent/MX2014013367A/es unknown
- 2013-04-30 KR KR20147033421A patent/KR20150004414A/ko not_active Withdrawn
- 2013-04-30 BR BR112014027337A patent/BR112014027337A2/pt not_active IP Right Cessation
- 2013-04-30 CN CN201380035099.2A patent/CN104583406A/zh active Pending
- 2013-04-30 EP EP17187348.2A patent/EP3272868A1/en not_active Ceased
- 2013-04-30 EA EA201492004A patent/EA201492004A1/ru unknown
- 2013-04-30 CA CA2872304A patent/CA2872304C/en active Active
- 2013-04-30 AU AU2013256471A patent/AU2013256471A1/en not_active Abandoned
- 2013-04-30 JP JP2015510380A patent/JP2015517466A/ja active Pending
- 2013-04-30 CN CN201811456141.9A patent/CN109481455A/zh active Pending
- 2013-04-30 WO PCT/US2013/038847 patent/WO2013166004A2/en not_active Ceased
- 2013-04-30 CA CA3173610A patent/CA3173610A1/en active Pending
- 2013-04-30 EP EP13721578.6A patent/EP2844757A2/en not_active Withdrawn
- 2013-04-30 HK HK15106884.9A patent/HK1206387A1/xx unknown
- 2013-04-30 EP EP20178501.1A patent/EP3736333A1/en active Pending
- 2013-04-30 US US14/397,815 patent/US20150238515A1/en not_active Abandoned
-
2016
- 2016-07-11 AU AU2016204832A patent/AU2016204832A1/en not_active Abandoned
- 2016-09-07 US US15/258,042 patent/US20180153919A1/en not_active Abandoned
-
2017
- 2017-11-14 AU AU2017261481A patent/AU2017261481A1/en not_active Abandoned
-
2020
- 2020-01-14 AU AU2020200247A patent/AU2020200247A1/en not_active Abandoned
-
2022
- 2022-05-04 AU AU2022202991A patent/AU2022202991A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013166004A2 (en) | 2013-11-07 |
| EP3736333A1 (en) | 2020-11-11 |
| JP2015517466A (ja) | 2015-06-22 |
| EP3272868A1 (en) | 2018-01-24 |
| HK1206387A1 (en) | 2016-01-08 |
| CN109481455A (zh) | 2019-03-19 |
| CA3173610A1 (en) | 2013-11-07 |
| KR20150004414A (ko) | 2015-01-12 |
| AU2017261481A1 (en) | 2017-11-30 |
| US20180153919A1 (en) | 2018-06-07 |
| AU2013256471A1 (en) | 2014-11-13 |
| WO2013166004A3 (en) | 2014-01-03 |
| CA2872304A1 (en) | 2013-11-07 |
| EA201492004A1 (ru) | 2015-08-31 |
| AU2020200247A1 (en) | 2020-02-06 |
| AU2016204832A1 (en) | 2016-07-28 |
| BR112014027337A2 (pt) | 2017-07-18 |
| US20150238515A1 (en) | 2015-08-27 |
| CN104583406A (zh) | 2015-04-29 |
| EP2844757A2 (en) | 2015-03-11 |
| AU2022202991A1 (en) | 2022-05-26 |
| CA2872304C (en) | 2022-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014013367A (es) | Composiciones organicas para tratar enfermedades relacionadas con kras. | |
| NZ731797A (en) | Dna-pk inhibitors | |
| MX377405B (es) | Compuestos para el tratamiento de cáncer. | |
| UA111604C2 (uk) | ЗАМІЩЕНІ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНОВІ СОЛІ | |
| NZ705910A (en) | Pyrrolobenzodiazepines and conjugates thereof | |
| MX2016007311A (es) | Metodos para tratar canceres. | |
| MX2011012584A (es) | Benzoxazepinas como inhibidores de pi3k/m tor, metodos para su uso y fabricación. | |
| ZA201103321B (en) | Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer | |
| MX377618B (es) | Métodos y composiciones para el tratamiento de la familia de tumores del sarcoma de ewing. | |
| PH12018502569A1 (en) | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | |
| MX336761B (es) | Compuestos para el tratamiento de cancer. | |
| MA40075A (fr) | Combinaisons pour traiter des cancers | |
| PH12013502334A1 (en) | Method for treatment of advanced solid tumors | |
| TN2015000543A1 (en) | Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor | |
| MX2014013763A (es) | Dosificacion y administracion de conjugados de scfv bi-especificos en combinacion con agentes terapeuticos anti-cancer. | |
| TN2016000442A1 (en) | Ang2 antibodies. | |
| WO2013066485A3 (en) | Compositions and methods for treatment of metastatic cancer | |
| WO2012166463A3 (en) | Aminooxazole inhibitors of cyclin dependent kinases | |
| PH12016502298A1 (en) | Vegfr2/ang2 compounds | |
| TN2015000544A1 (en) | Combination of a imidazopyridazine derivative and a mitotic agent for the treatment of cancer | |
| NZ742470A (en) | Combination therapy for cancer | |
| UA35392U (ru) | Способ комплексной терапии злокачественных опухолей и метастазов | |
| NZ627559A (en) | Inhibitors of notch signalling pathway and use thereof in treatment of cancers |